论文部分内容阅读
Due to its great contribution to the turnout cell survival, proliferation, and motility, epidermal growth factor receptor (EGFR) is, up to date, the most important therapeutic target of epithelial-originated cancer.Several variants of EGFR such as EGFRvⅢ (EGFR variant Ⅲ) have been reported to contribute a lot to the cancer initiation and progression.Since drugs targeting to EGFR often cause toxicity like skin rash, EGFR variants which were only detected in cancer tissues were regarded as more ideal therapeutic target.Nowadays, various monoclonal antibodies selectively targeting EGFR variants have been developed and tested.Results using the monoclonal antibodies to treat cancer cells expressing EGFR variants will be presented and discussed.